Repligen swings to Q3 net loss of $38.43 million
RGEN•Repligen reported a third-quarter net loss of $38.43 million, compared with a year-earlier profit, while revenue rose 11% to $209.3 million. Operating results turned to a $29.5 million loss, primarily due to a $41.24 million intangible asset impairment charge.
1. Quarterly results
Repligen swung to a third-quarter net loss of $38.43 million from a year-earlier profit. Revenue rose 11% year over year to $209.3 million, while operating results turned to a $29.5 million loss, primarily due to a $41.24 million intangible asset impairment charge.
2. Acquisition closed
Repligen closed its acquisition of BioLife Solutions on October 6, expanding its cell therapy consumables portfolio.
